Theralase Technologies Inc. V.TLT

Alternate Symbol(s): V.TLT.WT | TLTFF

Healthcare Medical Devices

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.

TSXV:TLT - Post by User

Theralase Technologies Inc.

<< Previous

Bullboard Posts

Next >>

Post by CancerSlayeron Dec 03, 2020 4:15pm

259 Views

Post# 32030765

U of M Funding

Been following TLT for a while now & excited about their potential.

To achieve the CRs they did with only 60% or less of the proper dose is a milestone in & of itself. With the specific protocol corrections made, Longs should be very encouraged moving forward on all fronts. Considering recently approved Keytruda only had a 1 yr CR of ~17% (based on 102 patients treated), I think TLT may be in the driver's seat with regards to BCG-unresponsive NMIBC.

Not sure if this was previously posted, but on the Covid-19 front, it was reassuring to see TLT/Dr. Coombs had recently gotten much needed federal funding.